NCT03620019 2026-03-27
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
9 trialsNCT03839459 2026-01-28
Denosumab for Smoldering Multiple Myeloma
University of Rochester
Phase 2 Completed
NCT02613416 2024-08-23
Dmab
Stony Brook University
Phase 2 Completed
NCT02366130 2021-10-07
Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03027557 2021-05-25
DENOCINA
Aalborg University Hospital
Phase 3 Completed
NCT01545648 2020-01-02
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
University of California, San Francisco
Phase 2 Terminated
NCT01952054 2019-11-22
Denosumab for Breast Cancer With Bone Mets
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02758132 2019-11-08
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
University of Hawaii
Phase 2 Terminated
NCT03070002 2018-11-20
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
Northwestern University
Phase 2 Terminated